Iovance Biotherapeutics, Inc.
General ticker "IOVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Iovance Biotherapeutics, Inc. does not follow the US Stock Market performance with the rate: -5.6%.
Estimated limits based on current volatility of 3.3%: low 2.24$, high 2.39$
Factors to consider:
- Total employees count: 838 (+50.4%) as of 2024
- US accounted for 98.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Need for additional capital, Operating losses, Manufacturing risks, Pandemic risks, Economic downturns and volatility
- Current price 37.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.57$, 10.92$]
- 2025-12-31 to 2026-12-31 estimated range: [3.76$, 9.20$]
Financial Metrics affecting the IOVA estimates:
- Positive: with PPE of -5.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.52 <= 0.04
- Positive: Shareholder equity ratio, % of 78.03 > 64.17
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -65.82 <= -0.76
- Positive: -14.19 < Investing cash flow per share per price, % of -4.51
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term IOVA quotes
Long-term IOVA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $1.19MM | $164.07MM |
| Operating Expenses | $398.88MM | $461.75MM | $559.35MM |
| Operating Income | $-398.88MM | $-460.56MM | $-395.28MM |
| Non-Operating Income | $2.98MM | $13.04MM | $20.27MM |
| R&D Expense | $294.78MM | $344.08MM | $282.34MM |
| Income(Loss) | $-395.89MM | $-447.52MM | $-375.00MM |
| Taxes | $0.00MM | $-3.48MM | $-2.83MM |
| Profit(Loss)* | $-395.89MM | $-444.04MM | $-372.18MM |
| Stockholders Equity | $499.64MM | $584.61MM | $710.40MM |
| Inventory | $0.00MM | $10.37MM | $51.52MM |
| Assets | $663.98MM | $780.35MM | $910.43MM |
| Operating Cash Flow | $-292.76MM | $-361.82MM | $-352.98MM |
| Capital expenditure | $20.43MM | $22.29MM | $11.07MM |
| Investing Cash Flow | $256.45MM | $-155.24MM | $-96.41MM |
| Financing Cash Flow | $190.15MM | $462.96MM | $390.66MM |
| Earnings Per Share** | $-2.49 | $-1.89 | $-1.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.